| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 10, 2013 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $0.92 | 165,375 | |
| May 17, 2012 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $1.93 | 21,000 | |
| December 12, 2011 | CMO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.00 | 35,687 | |
| December 7, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.07 | 12,000 | |
| December 6, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.31 | 7,000 | |
| December 6, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.31 | 74,125 | |
| December 6, 2011 | CFO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.15 | 28,636 | |
| August 16, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $3.00 | 46,907 | |
| March 23, 2011 | Director | Form 4 | Conversion of derivative security | 5,000 | $2.40 | 8,000 | |
| September 16, 2010 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $3.10 | 15,000 | |
| February 19, 2010 | Interim CAO, Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $2.94 | 15,000 | |
| August 17, 2009 | Director, President & CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $3.30 | 65,917 | |
| March 17, 2009 | Chief Financial Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.40 | 35,000 | |
| January 19, 2009 | VP & Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $2.72 | 19,000 | |
| January 19, 2009 | Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $2.72 | 30,000 | |
| October 9, 2007 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $5.84 | 104,010 | |
| October 9, 2007 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $5.84 | 109,010 | |
| October 2, 2018 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,100 | $2.70 | 20,787 | |
| October 3, 2006 | VP of Research & Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,100 | $2.44 | 9,100 | |
| October 3, 2006 | VP of Research & Development | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,100 | -- | 18,434 | |
| December 3, 2015 | Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 5,556 | $2.08 | 2,421,867 | |
| November 20, 2008 | VP & Chief Medical Officer | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,596 | $2.50 | 14,000 | |
| December 15, 2011 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,875 | $1.80 | 80,000 | |
| February 27, 2007 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,896 | -- | 103,362 | |
| February 25, 2020 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,000 | -- | 107,357 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
